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ABSTRACT
The crosstalk between chronic lymphocytic leukemia (CLL) cells and tumor 
microenvironment is essential for leukemic clone maintenance, supporting CLL 
cells survival, proliferation and protection from drug-induced apoptosis. Over the 
past years, the role of several soluble factors involved in these processes has been 
studied. CLL cells express higher levels of endothelin 1 (ET-1) and ETA receptor as 
compared to normal B cells. Upon ET-1 stimulation, CLL cells improve their survival 
and proliferation and reduce their sensitivity to the phosphoinositide-3-kinase δ 
inhibitor idelalisib and to fludarabine. Here, we demonstrate that CLL cells express 
not only ETA receptor but also ETB receptor. ET-1 acts as a homing factor supporting 
CLL cells migration and adhesion to microenvironmental cells. In addition, ET-1 
stimulates a pro-angiogenic profile of CLL cells increasing VEGF expression through 
hypoxia-inducible factor-1 (HIF-1α) accumulation in CLL cells. Macitentan, a specific 
dual inhibitor of ETA and ETB receptors, targets CLL cells affecting leukemic cells 
migration and adhesion and overcoming the pro-survival and proliferation signals 
mediated by microenvironment. Furthermore, macitentan cooperates with ibrutinib 
inhibiting the BCR pathway and with ABT-199 disrupting BCL2 pathway. Our data 
describe the biological effects of a new drug, macitentan, able to counteract essential 
processes in CLL pathobiology as survival, migration, trafficking and drug resistance. 
These findings envision the possibility to interfere with ET receptors activity using 
macitentan as a possible novel therapeutic strategy for CLL patients.
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INTRODUCTION
Recirculation from blood to tissue compartments 
represents an essential multistep process in the 
pathophysiology of chronic lymphocytic leukemia (CLL) 
cells. CLL cells distribution into tissues is tightly regulated 
by the expression of adhesive molecules and chemokine 
receptors on leukemic cells, by the establishment of 
chemokine gradients and by physical contact with 
components of extracellular matrix or cellular elements 
of stromal and immune system. Inside tissues, invading 
CLL cells disrupt the physiological architecture of bone 
marrow (BM) and lymph nodes (LN), creating a favorable 
soil for maintenance and progression of leukemic clone [1]. 
CLL cells form areas of larger proliferating cells, known 
as pseudofollicles, establishing intimate contact with the 
accessory cells that favor CLL survival and proliferation, 
promote clonal evolution and protect cells from the effect 
of chemotherapeutics. In addition, CLL cells shape the 
physiologic network of microvessels in infiltrated-BM 
and LN compartments, by destabilizing the mature and 
quiescent status of blood vessels and promoting endothelial 
cells (EC) proliferation, migration and branching to form 
a dense weaving of functionally impaired microvessels 
[2]. In this context, CLL cells are not innocent bystanders, 
but actively dominate and model the surrounding 
microenvironment to aberrantly orchestrate the function of 
supporting elements and EC [3].
Endothelin 1 (ET-1) is a 21-aa peptide that mediates 
its action by activating two G-protein-coupled receptor 
(GPCR) subtypes, ETA and ETB receptors (ETAR and 
ETBR) [4]. Extracellular binding of ET-1 to ET receptors 
activates a non-linear, highly interconnected signaling 
network. Major pathways and effectors downstream of 
ET receptors include mitogen activated protein kinase 
(MAPK) and phosphatidylinositol 3-kinase (PI3K)/AKT 
signaling pathways, adenylyl cyclase and phospholipases 
(PLCβ and PLA2) [5]. In addition to its role as a 
potent endogenous vasoconstrictor and mediator of 
cardiovascular and renal disorders, aberrant activation 
of ET-1 axis is now recognized as a common mechanism 
underlying the progression of various solid tumors, 
including ovarian, prostate, colon, breast, bladder and 
lung cancer [4]. The ET-1 signaling exerts a pleiotropic 
action, as it can activate proliferation, confer apoptosis 
resistance, stimulate new blood vessel formation, modulate 
immune responses and promote invasion and metastatic 
dissemination [6, 7]. Endothelin receptors can be activated 
in cancer cells either through autocrine production of 
abnormal levels of ET-1 or through ligand secretion 
from microenvironmental stromal cells in a paracrine 
loop. Endothelin receptor blockade represents the most 
promising approach in controlling the pleiotropic activities 
of ET-1 [5, 6, 8]. Macitentan (N-[5-(4-Bromophenyl)-6-[2-
[(5-bromo-2-pyrimidinyl)oxy]ethoxy]-4-pyrimidinyl]-N′-
propylsulfamide) is a novel potent dual ETA/ETB receptor 
antagonist as it inhibits [125I]-ET-1 binding to human 
recombinant ETA receptors with an IC50 of 0.2 nM and 
to ETB receptors with an IC50 of 391 nM. Treatment with 
macitentan leads to inhibition of growth, vascularization, 
intravasation, and metastatic dissemination, and also 
overcomes chemoresistance in solid tumors [9–13].
We previously demonstrated that CLL cells express 
higher levels of ET-1 as compared to normal B cells. 
ET-1 stimulation protects CLL cells from spontaneous 
apoptosis, stimulates proliferation and reduces leukemic 
cells sensitivity to the phosphoinositide-3-kinase δ 
inhibitor idelalisib and to fludarabine. Increased plasma 
levels of big ET-1, the precursor of ET-1, were detected in 
patients with unfavourable prognostic factors and shorter 
time to first treatment [14].
Here, we report that blocking ET receptors by 
macitentan hampers CLL cells migration, facilitates CLL 
cell death and overcomes survival advantage mediated by 
microenvironmental elements. Interestingly, macitentan 
interferes with B-cell receptor (BCR) activation and 
improves ABT-199 effects on CLL cells in contact 
with stromal supporting cells. We also demonstrate that 
macitentan impairs CLL cells proliferation, interferes with 
β-catenin signaling and reduces VEGF expression in CLL 
cells by decreasing hypoxia-inducible factor-1 (HIF-1α) 
accumulation. These findings envision the possibility to 
interfere with ET receptors activity using macitentan as a 
possible novel therapeutic strategy for CLL patients.
RESULTS
An increase in big ET-1 plasma levels 
accompanies CLL disease progression
We previously reported that patients with higher 
levels of big ET-1 in plasma at diagnosis experience 
shorter time to first treatment [14]. Here, we asked 
whether ET-1 accumulation in plasma effectively 
accompanies CLL natural history prior to treatment 
and whether its level is affected by ibrutinib treatment. 
So, we evaluated big ET-1 levels in plasma samples 
collected from patients at different clinical time points, 
including 12 monoclonal B-cell lymphocytosis (MBL), 
21 CLL at diagnosis, 21 CLL at progression prior to first 
treatment, and 28 CLL at relapse. In plasma samples of 
this cohort, big ET-1 was detectable at highly variable 
levels ranging from 0.5 to 31.2 pg/mL. We observed a 
significant increase in big ET-1 levels in CLL at diagnosis 
compared to MBL patients (3.5±0.4 pg/mL vs. 1.9±0.3 
pg/mL, respectively, p=0.006, Figure 1A). Interestingly, 
big ET-1 concentration doubled in plasma of CLL at 
first progression compared to CLL at diagnosis (7.9±0.8 
pg/mL vs. 3.5±0.4 pg/mL, respectively, p<0.0001). 
Accordingly, six patients with samples longitudinally 
collected at diagnosis and before first therapy showed 
increased levels of big ET-1 (Figure 1B). Furthermore, 
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we detected an additional increase of big ET-1 level at 
relapse after 1 or multiple therapies (11.1±1.4 pg/mL). 
Big ET-1 plasma levels did not correlate with white 
blood cell (WBC) count seen in CLL patients (p=n.s.). 
In particular, two untreated CLL patients with multiple 
samples longitudinally collected for 4 and 8 years during 
follow-up were analyzed. Although experiencing a 
progressive slow increase in WBC count, big ET-1 plasma 
levels remain constantly low (Supplementary Figure 
1). A representative CLL patient with multiple plasma 
samples collected at diagnosis and during 3-year follow-
up before therapy showed a roughly similar WBC count 
but a huge increase in big ET-1 levels from 0.9 to 88 pg/
mL (Supplementary Figure 1). These observations define 
ET-1 expression as a hallmark of CLL clone instead of a 
mere effect of CLL accumulation.
Lastly, we evaluated 5 patients receiving ibrutinib, 
finding a significant decrease of big ET-1 in plasma just 
after 1 month of treatment, despite the huge increase in 
lymphocytosis related to the treatment (p<0.05, Figure 
1C). As shown in Figure 1D, two representative CLL 
patients with plasma samples collected after long-term 
treatment with ibrutinib (6, 12 and 18 months) confirmed 
the decrease of big ET-1. Accordingly, ET-1 mRNA and 
protein expression in CLL cells was reduced by in vitro 
treatment with ibrutinib (Figures 1E and 1F). Overall, 
these findings strongly suggest a correlation between 
ET-1 expression and CLL progression in vivo. Due to 
the pleiotropic action of ET-1 signaling in several tumor 
settings, we asked if ET-1 may be involved in aberrant 
functions leading to CLL progression and relapse, i.e. 
prolonged survival, proliferation, microenvironmental 
support and chemoprotection.
Figure 1: ET-1 plasma levels are associated with CLL disease progression. (A) Dot plots depict the levels of big ET-1 in 
plasma samples collected from MBL (n=12), CLL at diagnosis (n=21), CLL at first progression (n=21) and CLL at relapse (n=28). 
(B) Measurement of big ET-1 levels in plasma samples longitudinally collected at diagnosis and pre-therapy in 6 patients. (C) Values of 
ET-1 plasma levels of pre-treatment and after one month of treatment with ibrutinib were evaluated in 5 different patients (n=5, p<0.05). 
 (D) For two representative CLL patients, plasma samples were collected pre-treatment and after different time-points of ibrutinib treatment. 
As shown after long-term treatment with ibrutinib, a decrease of big ET-1 was measured. (E and F) Bar diagrams show transcriptional 
levels of ET-1 measured by quantitative reverse-transcription PCR and ET-1 protein levels quantified by flow cytometry (MFIR) in CD19+ 
CLL cells cultured in vitro in presence or absence of ibrutinib (n=6, p<0.05).
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Macitentan interferes with survival signals in 
CLL
Here, we inspected CLL cells for the presence 
of ETB receptor finding that leukemic cells effectively 
express both ET receptors (Supplementary Figure 2). This 
feature prompted us to evaluate the effects of macitentan, 
a novel non-peptide double antagonist of ETAR and 
ETBR, on CLL cells. After investigating the effects of 
the inhibitor on CLL viability, we found that macitentan 
slightly favoured spontaneous apoptosis and affected 
ET-1 mediated survival advantage of CLL cells (Figure 
2A). Long-term survival of CLL cells is promoted by 
close contact with microenvironmental elements such as 
stromal cells. We wondered if macitentan may interfere 
with such mutualistic interactions, finding its ability 
to almost completely nullified stromal cell-mediated 
survival advantage after 4 days of co-culture (Figure 2B). 
We investigated the effect of macitentan on signaling 
pathways involved in this crosstalk and we found a strong 
Figure 2: Macitentan interferes with survival signals in CLL cells. (A) CLL cells were cultured with the addition of recombinant 
ET-1 peptide either in presence or absence of macitentan. Histograms represent mean±SEM at 24h of 6 CLL patients evaluated in 3 
independent experiments (P*<0.05, **P<0.01). (B) CLL cells (n=5), pretreated or not with macitentan, were cultured on 3T3 cell line layer 
for 96 hours. Bar diagrams represent data as mean±SEM of 5 CLL. (C) CD19+ CLL cells were cultured either alone or in contact with 3T3 
in presence or absence of macitentan for 24 hours. Immunoblots show pAKT, pERK and the corresponding total protein, actin and CD19 
in one representative CLL samples. Bar diagrams depict densitometric quantification of bands relative to pAKT/tot AKT, and pERK/tot 
ERK ratio of the corresponding condition, normalized on CD19 amount and β-actin. Data are presented as mean ± SEM of 5 different CLL 
samples (n=6, *P<0.05; ** P<0.01).
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induction of AKT and ERK phosphorylation in CLL cells 
cultured with 3T3 compared to control (n=6, p<0.01 and 
p<0.05). Moreover, in presence of macitentan a significant 
decrease of AKT and ERK phosphorylation was detected 
in the co-culture model (n=6, p<0.05, Figure 2C).
Beside cellular interplay, BCR activation represents 
a key driver for maintenance and progression of CLL 
cells. We stimulated BCR signaling on CLL cells by 
using a F(AB’)2 fragment to human IgM, observing a 
significant increase in ET-1 secretion by leukemic cells 
(Figure 3A). In addition, BCR triggering led to an increase 
in CLL survival that was partially hampered by macitentan 
alone through interference with BTK phosphorylation and 
ERK signaling pathway (Figures 3B-3C). The synergistic 
combination of macitentan with the BTK inhibitor 
ibrutinib completely nullified BCR-mediated survival 
and intracellular signaling, indicating the convergence of 
BCR and ET receptors downstream pathways in CLL cells 
(Figures 3B-3C).
A promising novel therapeutic strategy for CLL is 
to target the apoptotic machinery directly by the so-called 
BH3-mimetics, i.e. BCL2-specific compound ABT-199 
or venetoclax. Interestingly, an additional synergistic 
reduction in CLL survival was detected in an overnight 
Figure 3: Macitentan blocks BCR signaling and promotes apoptosis in combination with ibrutinib and ABT-199 in 
CLL cells. (A) Big ET-1 level was measured in conditioned medium collected from unstimulated CLL cells or stimulated with F(ab’)2 
fragment to human IgM (n=6, P<0.05). (B) CLL cells were pre-treated with macitentan or ibrutinib or both for 1 hour and then stimulated 
with anti-IgM. CLL cells viability was measured after 24h, 48h and 72h. Bar diagrams show cell viability as mean±SEM at 48 hours of 5 
CLL patients (*P<0.05). (C) Serum-starved CLL cells were pretreated or not with ibrutinib, or macitentan or combination of both for 1 hour 
before stimulation with anti-IgM for 10 minutes. The immunoblots depict BTK, ERK phosphorylation in two representative cases. Below, 
box plots show densitometric quantification of bands relative to pBTK/tot BTK and pERK/tot ERK normalized on β-actin (n=5, *P<0.05). 
(D) CLL cells were pre-treated with macitentan for 1 hour and ABT-199 was added in culture. Bar diagrams show CLL cells viability 
measured after 24h of culture (n=6, *P<0.05, **P<0.01). (E) CLL cells were pre-treated with macitentan for 1 hour and then cultured onto 
3T40L cell layer for 3 hours. Then, ABT-199 was added and CLL cells viability was measured after 24h, 48h and 72h. Bar diagrams show 
CLL cells viability as mean±SEM after 48 hours of culture (n=4, *P<0.05, **P<0.01). (F) Serum-starved CLL cells were either pre-treated 
or not with macitentan for 1 hour and then cultured for 24 hours with ET-1. On the left, bar diagram depicts densitometric quantification of 
bands relative to BCL-2 either in presence or absence of the corresponding treatment, normalized on β-actin. Data are presented as mean ± 
SEM of 3 different CLL samples (*P<0.05). On the right, two representative samples are depicted.
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incubation when macitentan was used in combination to 
0.001μM BCL2 inhibitor ABT-199 as compared to ABT-
199 alone (Figure 3D). Moreover, a reduction in CLL 
resistance to 1μM ABT-199 mediated by contact with 
stromal cells expressing CD40L (3T40L) was also found 
with the addition of macitentan (Figure 3E). Accordingly, 
ET-1 stimulation increases BCL2 expression in CLL and 
treatment with macitentan prevents this unwanted effect 
that limits ABT-199 efficacy towards CLL cells (Figure 
3F).
Macitentan counteracts CLL proliferation by 
inhibiting β-catenin accumulation
A fraction of CLL cells inside tissues are 
proliferating, being the cell birth rate 0.1 to 1% of the 
CLL clone per day. Far from being a marginal event 
in CLL pathobiology, cell proliferation contributes to 
clonal evolution of leukemic clone, improvement in 
disease aggressiveness, relapses after treatments and 
acquisition of chemoresistance. We asked if interfering 
with ET-1 signaling through macitentan could 
counteract the proliferative promptness of CLL cells 
in contact with stromal cells. As shown in Figure 4A, 
the percentage of divided CLL cells after 72 hours co-
culture in contact with 3T3 cell layer was significantly 
reduced in the presence of macitentan from 25% to 18%. 
Due to the established cooperation between ET-1 and 
β-catenin signaling pathways, we evaluated the ability 
of macitentan to interfere with β-catenin accumulation 
in CLL cells. We found that macitentan activates the 
glycogen synthase kinase 3β (GSK3β) by reducing its 
phosphorylation at serine 9. Thus, activated β-catenin 
destruction complex leads to proteasomal degradation 
of β-catenin, which was detected at lower levels in CLL 
cells (Figure 4B).
Macitentan restrains CLL adhesion and 
movement towards ET-1 and CXCL12
Homing of CLL cells to the bone marrow and 
lymph node compartments represents a crucial step in 
disease progression. We wondered if ET-1 signaling has 
a role in CLL trafficking. First, we found that CLL cells 
migrate toward ET-1 in a dose-dependent manner (Figure 
5A). Blocking ET receptors on CLL cells by macitentan 
restrains CLL movement to ET-1 (Figure 5A). Stimulation 
of CLL cells with ET-1 was able to induce a slight increase 
of CXCR4 expression (n=5, P<0.05, data not shown). On 
this line, treatment of CLL cells with macitentan was able 
to interfere with another crucial chemokine CXCL12, 
secreted by stromal cells and well known to be essential 
for CLL migration inside tissues (Figure 5B). Interestingly, 
macitentan mimics ibrutinib effect on CXCL12-mediated 
migration, further improving ibrutinib effect when used 
in combination (from 356±86% for CXCL12-mediated 
migration to 144±32% for ibrutinib alone and to 124±30% 
for combination, p=0.032, Figure 5B). We demonstrated 
that macitentan interferes with CXCR4 signaling 
pathways. Treating CLL cells with macitentan for 4 hours 
and then stimulating them with CXCL12 for 10 minutes, 
phosphorylation of AKT was significantly decreased 
(Figure 5C, n=4, P<0.05). Accordingly, circulating CLL 
fraction with higher levels of CXCR4, the CXCL12 
receptor, on the cellular surface showed increased density 
of both ET receptors, likely defining a subpopulation of 
leukemic cells with more promptness to taste migratory 
signals (Figure 5D).
We then demonstrated that ET-1 signaling 
improves the adhesive capacity of CLL cells, as inferred 
on the basis of the following observations. First, 
macitentan significantly decreases the extent of CLL 
cells able to firmly attach to stromal and endothelial cell 
supports (Figures 6A-6B). In particular, a reduction of 
30%, 40% and 35% in CLL cells in contact with 3T3 
murine stromal cells, HUVEC endothelial cells and 
HS-5 human stromal cells was measured. Then, an 
increase in CD49d (also known as VLA-4) expression 
was measured when CLL cells were stimulated with 
ET-1 (Figure 6C). On the contrary, we have not found 
the modulation of other integrins as CD11a, CD29, 
CD49c and CD18 after stimulation with ET-1 (p=ns, 
n=7, data not shown). Accordingly, CLL fraction in 
peripheral blood with higher density of CD49d showed 
increased levels of ET receptors (Supplementary Figure 
3). Lastly, as shown in Figure 6D, ET-1 stimulation 
activates intracellular key molecules involved in CLL 
adhesion, as focal kinases.
All together, these findings depict ET-1 signaling 
as a CLL migration factor, able to regulate the 
interactions between leukemic cells and surrounding 
microenvironment by modulating changes in intracellular 
adhesive signaling and cell surface adhesive molecules.
ET receptor engagement promotes VEGF 
expression in CLL cells
ET-1 has been shown to promote angiogenesis 
by directly controlling EC proliferation and indirectly 
by inducing vascular endothelial growth factor (VEGF) 
expression [15]. In CLL, ET-1 signaling promotes HIF-
1α accumulation as demonstrated by flow cytometry 
(Figure 7A) and immunofluorescence (Figure 7B). 
HIF-1α transcript levels were not affected by ET-1 
treatment in CLL cells (data not shown), suggesting that 
its accumulation may be due to an increased HIF-1α 
stability as previously reported in melanoma cells [16]. 
We also detected higher VEGF expression in CLL cells 
upon exposure to ET-1 (Figure 7C). Treating CLL cells 
with macitentan reduces their pro-angiogenic profile by 
interfering with VEGF expression (Figure 7C).
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DISCUSSION
Aberrant activation of ET-1 axis is now recognized 
as a common mechanism underlying the progression of 
several solid tumors. Binding two distinct G protein-
coupled receptors (GPCRs), ETAR and ETBR, ET-1 
activates a plethora of intracellular signals strictly 
interconnected with various well-characterized pathways 
that act in a synergistic and combinatorial manner to favor 
survival and proliferation, adhesion and migration and 
to dysregulate the balance of angiogenesis and immune 
protection [6]. We investigated the role of ET-1 axis in 
CLL setting evaluating the possibility to interfere with 
these signals by using macitentan, a novel potent dual ETA/
ETB receptor antagonist.
We demonstrated that CLL patients experience a 
progressive big ET-1 increase in plasma during the natural 
disease progression from MBL condition to CLL diagnosis 
and further when uncontrolled CLL cell accumulation 
needs therapeutic intervention. When CLL clone relapses 
after chemotherapy an additional increase in big ET-1 was 
detected, whereas disease control exerted by ibrutinib 
treatment rapidly reduced big ET-1 levels. Higher big 
ET-1 levels detected in CLL patients at diagnosis predict 
shorter time to first treatment and characterize CLL clone 
with adverse prognostic features such as unmutated 
immunoglobulin genes and deletion 17p and 11q as 
demonstrated in a previous study [14]. Synthesis of the 
biologically active ET-1 peptide is a multistep process. 
The primary translation product of ET-1 gene is the 
212-aa prepro ET-1, which is cleaved by an endothelin 
converting enzyme (ECE-1) to form the 38-aa big ET-1 
and then to the biologically active 21-aa ET-1 peptide [4]. 
We assessed big ET-1 levels instead of the active peptide 
ET-1 due to the very low levels of ET-1 in plasma and the 
short half-life (1.5 minutes) [17]. Our results are in line 
with a well-documented association between circulating 
big ET-1, adverse prognostic features and shorter survival 
in patients with various solid tumors [18–21]. Altogether 
these findings strongly suggest an impact of ET-1 axis in 
Figure 4: Macitentan affects CLL proliferation mediated by contact with stromal cells. (A) CFSE-labeled CLL cells were 
cultured for 4 days alone in complete medium (control) or on 3T3 murine stromal cell layers. Where indicated, CLL cells were incubated 
for 1 hour with macitentan before co-culture. The proliferative measure was inspected for 4 days, gating the CD19+ live CLL cells. 
The histograms represent cumulative data at 96 hours of 3 independent experiments by using 3 CLL patients. Data are shown as mean 
values±SEM of the percentage of dividing CLL cells. The percentage of dividing CLL cells cultured alone was irrelevant. (B) CLL cells 
were either pre-treated or not with macitentan for 1 hour and then cultured for 24 hours. Panel B shows two representative western 
blots blotted for pGSK3β and β-catenin. Bar diagrams depict densitometric quantification of bands relative to pGSK3β/total GSK3β and 
β-catenin either in presence or absence of macitentan, normalized on β-actin. Data are presented as mean ± SEM of 4 different CLL samples 
(*P<0.05).
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CLL pathobiology and envision the possibility to explore 
a novel class of agents interfering with ET receptors, also 
in combinations with new drugs currently available or 
actually tested in clinical trials such as ibrutinib, idelalisib 
and ABT-199.
We speculated that disrupting ET-1 signaling 
pathways may concomitantly affect a panel of aberrant 
biological functions typical of CLL cells. Resistance to 
apoptosis is a hallmark of CLL disease and it is induced 
by intrinsic genetic lesions and extrinsic signals from 
microenvironmental elements that cooperate to keep 
active intracellular pro-survival pathways such as PI3K-
Akt signaling or up-regulate anti-apoptotic molecules 
such as BCL-2, BCL-XL and survivin. ET-1 acts as an 
anti-apoptotic factor in different cell types by modulating 
PI3K-dependent Akt activation and by increasing pro-
survival factors [14, 22–24]. We found that macitentan 
induces CLL spontaneous apoptosis and hampers the 
survival advantage acquired by CLL cells both in contact 
with stromal cells and in response to BCR activation. 
In CLL, ET-1 signaling converges to BCR intracellular 
cascade. As consequence, macitentan cooperates with 
ibrutinib reducing the phosphorylation of crucial tyrosine 
kinases in BCR signaling, i.e. BTK and ERK.
Moreover, ET-1 induces the expression of anti-
apoptotic protein BCL-2, thus contributing to apoptosis 
resistance in CLL cells. This leads to the possibility 
that ET-1 signaling may be partially involved into CLL 
resistance to BCL-2-specific compound ABT-199. 
Beside the exciting clinical results of venetoclax (ABT-
199), it has to be considered that some patients harbor 
sub-populations of resistant cells that mediate disease 
Figure 5: Macitentan affects CLL cell chemotaxis towards ET-1 and CXCL12. (A) CLL cells were allowed to migrate 
towards different doses of ET-1: 1nM, 10nM and 100 nM, or control medium without chemokine. CLL cells were pre-incubated or not 
with macitentan and migration to 100nM ET-1 was inspected. The bar diagram represents the mean migration (± SEM) of CLL cells from 
6 different patients (*P<0.05, **P<0.01). (B) CLL cells were treated with ibrutinib, macitentan or a combination of both and then allowed to 
migrate towards CXCL12. The bar diagram represents the mean migration (± SEM) of CLL cells from 8 different patients (*P<0.05). (C) 
CD19+ CLL cells isolated from 5 patients were treated with macitentan for 4 hours and then stimulated with CXCL12 for 10 minutes. On 
the left, bar diagrams represent densitometric quantification of bands relative to pAKT/total AKT normalized on β-actin. Data are presented 
as mean ± SEM of 5 different CLL samples (*P<0.05). On the right, immunoblots show phosphorylation of AKT for one representative 
CLL sample. (D) PBMCs isolated from 8 CLL patients were stained for CD19. CD19+ cells, stained for CXCR4, were divided in positive 
and negative. For each group, MFI of ETA receptor and ETB receptor was measured. In all experiments, an isotype control sample for each 
condition was acquired to exclude autofluorescence background. Box blots show the MFI of ETAR and ETBR in the CXCR4+ and CXCR4- 
populations (n=8, *P<0.05, **P<0.01).
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recurrence [25, 26]. Venetoclax resistance seems to be 
mediated by microenvironmental signals that lead to 
BCL-2, BCL-XL and MCL-1 accumulation in leukemic 
cells [27–30]. We demonstrated that macitentan affects 
ET-1-mediated BCL-2 accumulation and further increases 
ABT-199-mediated apoptosis in CLL cells. Interestingly, 
a reduction in CLL protection mediated by stromal cells 
against ABT-199 effect was detected in combination 
with macitentan. ET-1 signaling has been correlated to 
acquisition of chemo-resistance in several solid tumors 
such as ovarian, prostate, colon, cervical carcinoma 
and osteosarcoma [12, 31–35]. In ovarian cancer, ET-1 
confers resistance to paclitaxel-induced apoptosis by a 
BCL-2-dependent mechanism that can be reversed by 
the addition of specific ETAR antagonist [36]. In mice 
models, macitentan sensitizes ovarian and breast cancer 
cells to paclitaxel and cisplatinum and glioblastoma cells 
to temolozomide [9, 10, 12, 13, 37].
CLL cells shape the architecture of infiltrating 
tissues generating follicular-like structures known 
as proliferation centers. Inside proliferation centers, 
leukemic cells engage close connections with surrounding 
accessory cells of stromal and immune systems that drive 
proliferative stimuli. Leukemic cells of each patient 
had definable and often substantial birth rates, varying 
from 0.1% to greater than 1.0% of the entire clone per 
day. Moreover, high levels of CLL proliferation are 
correlated with worse prognosis [38]. Accordingly, higher 
Figure 6: Macitentan inhibits CLL cell adhesion to endothelial and stromal cells. (A) CLL cells were treated with macitentan 
and allowed to adhere to 3T3, HUVEC and HS-5 for 4 hours. The bar diagrams represent the mean relative adhesion (±SEM) of CLL 
cells in the presence of macitentan compared with control (n=6, *P<0.05; **P<0.01). (B) Representative phase contrast photomicrographs 
demonstrating CLL cell adhesion to 3T3, HUVEC and HS-5 either treated or untreated (control) with macitentan. (C) CLL cells were 
stimulated for 24h with ET-1 and then analyzed for CD49d expression. Values of untreated and treated samples are connected by lines (n=4, 
*P<0.05, **P<0.01). On the right, a representative histogram shows the fluorescence intensity of CD19+ CLL cells after treatment with ET-1 
stained with anti-CD49d antibody. (D) Bar diagrams depict densitometric quantification of bands relative to pGSK3β/tot GSK3β, pFAK/
tot FAK and pAKT/tot AKT ratios either in presence or absence of ET-1 stimulation, normalized on β-actin. Data are presented as mean ± 
SEM of 5 different CLL samples (*P<0.05). On the bottom, immunoblots show pGSK3β, pFAK and pAKT in presence of ET-1 stimulation 
in 3 representative CLL samples.
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circulating Ki-67 index was significantly associated 
with shorter survival [39]. It turns out that proliferation 
is not a marginal phenomenon in CLL, but represents a 
crucial step for disease accumulation and clonal evolution. 
We demonstrated that macitentan interferes with CLL 
proliferation driven by stromal cells. ET-1 acts as a 
mitogenic signal both in normal cells including fibroblasts 
and EC and in various tumor cells throughout the elevation 
of intracellular free Ca2+, activation of mitogen-activated 
protein kinases and β-catenin signaling [6]. Macitentan 
reduces β-catenin accumulation in CLL by decreasing 
the phosphorylation of GSK3β, and thus activating the 
destruction complex. The interference with β-catenin 
accumulation together with the inactivation of MAPK and 
PI3K signaling pathways may account for the reduction in 
CLL proliferation mediated by macitentan.
The necessity of CLL cells to localize into tissues 
in order to establish crucial mutualistic crosstalk with 
tumor microenvironment represents the Achilles’ heel of 
leukemic clone. Recirculation of CLL cells from peripheral 
blood to tissue compartment requires the cooperation 
between several chemokine receptors and adhesion 
molecules. In particular, the chemokine receptor CXCR4 
is expressed at high levels in CLL cells and mediates CLL 
cell chemotaxis to CXCL12, migration across vascular 
endothelium, and then beneath and underneath CXCL12-
secreting stromal cells [40]. In addition, the α4β1 integrin 
VLA-4 (CD49d) cooperates with chemokine receptors 
in CLL cell adhesion to stromal cells. We demonstrated 
that ET-1 acts as a chemotactic and adhesive factor 
for CLL cells. Indeed, ET-1 promotes CLL migration, 
favors CD49d expression in CLL cells and mediates 
intracellular phosphorylation of focal adhesion kinase 
(FAK). Macitentan restrains CLL movement to both ET-1 
and CXCL12, interfering with CXCR4/CXCL12 axis. In 
Figure 7: ET-1 stimulation induces a pro-angiogenic profile in CLL cells. (A) Box plot represents the MFIR of HIF-1α in 7 CLL 
samples either stimulated or not stimulated with ET-1 for 30 minutes. On the right, histograms show the fluorescence intensity of CD19+ CLL 
cells after treatment with ET-1 stained with anti-HIF-1α antibody. (B) CLL cells were allowed to adhere on the coverslip and then stimulated 
for 30 minutes with ET-1. HIF-1α induction was analyzed by immunofluorescence microscopy. Three representative CLL samples are shown. 
On the right, bar diagram represents quantification of cell staining, as mean value obtained from 5 different fields at 400X magnification 
normalized on control (100%, untreated sample). (C) CD19+ CLL cells were stimulated or not with ET-1 either in presence or absence of a 
pre-treatment with macitentan. Bar diagram depicts VEGF transcriptional levels (n=5, *P<0.05).
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addition, macitentan reduces CLL adhesion to endothelial 
and stromal cells.
Preclinical results indicate good efficacy when 
macitentan was administered in combination with 
chemotherapy in solid tumors. Recently, macitentan 
plus paclitaxel significantly increased overall survival 
by producing complete responses in all mice tested 
harboring brain metastasis of breast and lung cancer [37]. 
In chemoresistant ovarian cancer, tumor suppression and 
reduction of metastatic progression were reported with co-
treatment of macitentan and cisplatinum [12]. In another 
study, the majority of mice (96%) bearing orthotopically 
implanted glioblastoma-resistant cancer cells and treated 
with macitentan and temolozomide had no evidence of 
disease [9]. Beside these promising preclinical findings 
in other tumor settings, the use of dual ETAR and ETBR 
antagonists could offer the advantage in CLL to target 
not only tumor cells (which express both receptors) but 
also surrounding EC, stromal cells and immune cells, 
which all expressed ETBR. Indeed, macitentan induces 
apoptosis in tumor-associated endothelial cells [10, 13, 
37]. Moreover, ET-1 acts on cancer-associated fibroblasts 
to promote the formation of supporting stroma [41] 
and favors macrophage migration and production of 
inflammatory mediators, while inhibits T cell homing to 
tumors [42]. Further studies are necessary to evaluate the 
effects of macitentan treatment on immune elements in 
CLL patients.
In conclusion, our findings demonstrate that 
macitentan impairs the pleiotropic actions of ET-1 
signaling, concomitantly affecting multiple aberrant 
functions of CLL cells, i.e. survival, proliferation, 
angiogenesis, migration and chemoresistance. The 
possibility to interfere with multiple signals directly 
involved in CLL maintenance and progression and 
also with the mutualistic dialogue between CLL and 
microenvironmental accessory cells by using macitentan, 
also testing it in combination strategies with novel 




Blood samples from CLL patients were obtained 
from the Hematology Unit of Modena Hospital in Italy 
with a protocol approved by the Institutional Review Board. 
All patients tested in in vitro experiments were untreated at 
blood collection, whereas CLL patients relapsed from 1 or 
multiple treatments or treated with ibrutinib were included 
in the evaluation of big ET-1 plasma levels. All patients 
provided written informed consent in accordance with the 
declaration of Helsinki. Peripheral blood mononuclear cells 
(PBMCs) were isolated by density gradient centrifugation 
and used fresh or cryopreserved in liquid nitrogen. Plasma 
was obtained centrifuging peripheral blood for 15 minutes at 
2000 rpm and then stored at -80°C. To purify CLL, PBMCs 
were incubated with CD19-specific Microbeads (Miltenyi 
Biotec, Bergisch Gladbach, Germany) and separated by 
AutoMACS (Miltenyi Biotec), obtaining a purity >99% 
as assessed by flow-cytometry. Macitentan and ibrutinib 
were purchased by Selleckchem (Munich, Germany) and 
dissolved in DMSO, used as vehicle. ET-1 peptide (H-
6995) was obtained by Bachem (Bubendorf, Switzerland) 
and solubilized in 5% acetic acid, used as vehicle in all 
experiments.
Migration assays
To test migration, CLL cells were pre-treated with 
1 μM macitentan and/or 0.5 μM ibrutinib or vehicle for 
1 hour. ET-1 at increasing doses of 1 nM, 10 nM and 
100 nM or CXCL12 (also known as stromal-cell derived 
factor-1, SDF-1α) (Peprotech, Rocky Hill, NJ, USA) at 
200 ng/mL were used as chemoattractant and placed in 
RPMI+0.2% BSA (600 μL) in the bottom compartment of 
Millicell Cell Culture Inserts (Millipore, Billerica, USA). 
Then, 200 μL of cell suspension (3x105 cells) were added 
to the upper inserts. The chambers were incubated at 37°C 
in humidified air with 5% CO2 for 24 hours. Migrated 
cells were labeled with 4 μM Calcein-AM (Sigma-
Aldrich, St. Luis, MO, USA) for 45 min and quantified by 
fluorescence plate reader Infinite200 (Tecan, Männedorf, 
Switzerland) at an excitation wavelength of 485 nm and an 
emission of 520 nm.
Adhesion assays
CLL cells were added onto the confluent layers of 
Human Umbilical Vein Endothelial Cells (HUVEC) or 
3T3 murine stromal cells or HS-5 human stromal cells and 
allowed to adhere for 4 hours at 37°C. Prior to incubation, 
CLL were treated with 1 μM macitentan or vehicle for 
1 hour. Then, CLL firmly adherent to HUVEC, 3T3 and 
HS-5 layer were counted by staining with APC-conjugated 
anti-CD19 antibody (Miltenyi Biotec) as previously 
described [43].
Viability assays
CLL viability was inspected in three experimental 
settings. First, cells were incubated or not with 1 μM 
macitentan or DMSO for 1 hour at 37°C following 
stimulation with 100 nM ET-1 or vehicle for 24 hours. In 
a second setting, CLL cells were incubated for 1 hour at 
37°C with macitentan or DMSO then plating cells onto 
confluent 3T3 murine stromal cells and assessing CLL 
viability until 96 hours. 3T3 cells were excluded using a 
morphological gate, as their relative size and granularity 
(forward scatter and side scatter) is clearly distinguishable 
from that of lymphocytes. In some experiments, ABT-
199 was added at a dose of 1 nM in CLL cells cultured 
Oncotarget90024www.impactjournals.com/oncotarget
alone and 1μM in CLL cells co-cultured with 3T3. In a 
third setting of experiment, CLL cells were pre-incubated 
with 1 μM macitentan and/or 0.5μM ibrutinib or vehicle 
for 1 hour at 37°C, then stimulating or not cells with 10 
μg/mL goat F(AB’)2 fragment to human IgM (5FCμ) 
(MP Biomedicals, Santa Ana, CA, USA) and measuring 
CLL viability until 96 hours. Apoptotic cell death was 
analyzed using Annexin V-FITC and Propidium Iodide 
(PI) staining (eBioscience, San Diego, CA, USA). Events 
were acquired using a FACSCalibur cytometer (Becton 
Dickinson) and then analyzed by FlowJo Software (Tree 
Star, Ashland, OR, USA). The combination between 
ibrutinib and macitentan or ABT-199 and macitentan was 
defined synergistic according to the multiplicative model 
proposed by Larsson R et al [44].
Immunoblotting
Purified CLL cells were exposed to 100 nM ET-1 for 
30 minutes. In another experiment, CLL cells were pre-
incubated with 1 μM macitentan and/or 0.5μM ibrutinib 
or vehicles for 1 hour at 37°C, then stimulating or not 
cells with 10 μg/mL goat F(AB’)2 fragment to human 
IgM (5FCμ) for 10 minutes. Cells were then lysed on 
ice for 10 minutes with lysis buffer supplemented with 
dithiothreitol and protease inhibitor cocktail (BioVision, 
Milpitas, CA, USA). Proteins (80μg/lane) were 
electrophoresed on 4% to 20% SDS-polyacrylamide 
gradient gels (Biorad laboratories, Hercules, CA, USA). 
Membranes were immunoblotted with primary antibodies 
listed in Supplementary Table 1. Then, membranes were 
incubated with species-specific horseradish peroxidase 
(HRP)-conjugated secondary antibody (diluted 1:50000; 
GE Healthcare, Uppsala, Sweden) for 1 hour and 
developed using HRP conjugates WesternBright Sirius 
(Advansta, Menlo Park, CA, USA). Images were acquired 
and analyzed using Image Lab Software v.3.0 (Biorad 
Laboratories).
Immunofluorescence
HIF-1α expression in CD19+ CLL cells was 
evaluated by an intracytoplasmatic immunofluorescence 
staining. CLL cells were plated in RPMI+10% FBS 
on coverslip in a 24-well plate and let them to adhere 
overnight. The day after, cells were stimulated with 100 
nM ET-1 or vehicle. After 4 hours, cells were fixed. After 
washes, anti-HIF-1α antibody (Novus Biologicals) was 
loaded on coverslips and incubated overnight at +4°C. 
The next day, the coverslips were washed and incubated 
with Alexa-Fluor 488 conjugated secondary antibody 
(Life Technologies). The immunofluorescent images were 
visualized with Leica DMRA2 fluorescence microscopy 
(Leica Microsystems) equipped with a DC350 FX camera. 
Pixel intensity analyses were performed using the ImageJ 
(downloadable at http://rsbweb.nih.gov/ij/) software. 
Mean pixel intensity was calculated by defining a region 
of interest (ROI) and measuring green fluorescence pixel 
intensity. Results are expressed as fold change compared 
to untreated control.
Enzyme-linked immunosorbent assays
Big ET-1 levels in conditioned media and plasma 
samples were measured using big Endothelin-1 (human) 
EIA kit (Enzo Life Sciences, Farmingdale, NY, USA). The 
mean minimum detectable dose was 0.23 pg/mL. Each 
sample was tested in duplicate and concentrations were 
reported in pg/mL.
Quantitative PCR
RNA was extracted with the RNeasy Plus Mini kit 
(Qiagen, Valencia, CA, USA) and reverse transcribed 
using SS VILO Mastermix (Life Technologies). Ten 
nanograms per reaction of cDNA were analyzed in Real-
Time PCR on LightCycler 480 v.2 (Roche) using SYBR 
Green Master Mix (Applied Biosystems) and specific 
primers designed for ET-1 and VEGF or the internal 
control Glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) gene. All samples were run in duplicate. 
Comparative relative expression was calculated using the 
delta Ct method and normalized to a calibrator sample 
(Universal Human Reference RNA; Stratagene, Cedar 
Creek, TX). To exclude non-specific amplification and 
primer-dimer formation, a dissociation curve analysis was 
performed and PCR products were tested by agarose gel 
electrophoresis.
Flow cytometry
PBMCs from CLL patients were incubated with 
APC-conjugated anti-CD19 antibody (Becton Dickinson, 
San José, CA, USA), PE-conjugate anti-CD184 (CXCR4) 
or PE-conjugate anti-CD49d (Miltenyi Biotec) and rabbit 
ETBR (N-terminal) antibody (Sigma-Aldrich, St. Luis, 
MO, USA) or rabbit polyclonal ETAR antibody (Abgent, 
S.Diego, CA, USA) for 30 min in ice followed by FITC-
conjugated Goat anti-rabbit Ig for 30 min in ice (Becton 
Dickinson). For each sample an isotype control was 
prepared in parallel. In other experiments, CLL cells 
were incubated for 30 minutes with 100 nM ET-1 or 
vehicle (control sample), then stained with the following 
antibodies and corresponding isotype controls: anti-HIF-
1α antibody (Novus Biologicals, Abingdon, UK) followed 
by FITC-conjugated goat anti-rabbit staining.
Proliferation assay
CFSE (5-[and 6]-Carboxyfluorescein diacetate 
succinimidyl ester; eBioscience) dilution assay was used 
to trace cell division by flow cytometry. CD19+ CLL cells, 
stained with CFSE, were incubated or not with macitentan 
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and then plated onto the confluent 3T40L layer. The 
proliferative measure was evaluated after 4 days, gating 
the CD19+ alive CLL cells, and analyzed using Modfit 
software. For the analysis, every generation of cells 
appears as a different peak on a flow cytometry histogram.
Statistical analyses
Data were analyzed using SPSS version 20.0 (SPSS, 
Chicago, IL, USA). In some experiments, results were 
normalized on control (100%) (vehicle-treated samples). 
Normalization was performed by dividing the value of a 
particular treated sample to the value of the corresponding 
sample treated with vehicle. P values were calculated by 
Student t test (*P<0.05, **P<0.01). Data are presented as 
mean and standard error of the mean (SEM) is depicted 
as error bars.
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